Risk factors for venous thrombosis.
| Acquired . | Inherited . | Mixed/Unknown . |
|---|---|---|
| Abbreviations: TAFI, thrombin activatable fibrinolysis inhibitor; APC, activated protein C. | ||
| Age | Antithrombin deficiency | Hyperhomocysteinemia |
| Previous thrombosis | Protein C deficiency | High levels of factor VIII |
| Immobilization | Protein S deficiency | APC-resistance in the |
| Major surgery | Factor V Leiden | absence of factor V Leiden |
| Orthopedic surgery | Prothrombin 20210A | High levels of factor IX |
| Malignancy | Dysfibrinogenemia | High levels of factor XI |
| Oral contraceptives | High levels of TAFI | |
| Hormonal replacement therapy | ||
| Antiphospholipid syndrome | ||
| Essential thrombocythemia | ||
| Polycythemia vera | ||
| Paroxysmal nocturnal hemoglobinuria | ||
| Acquired . | Inherited . | Mixed/Unknown . |
|---|---|---|
| Abbreviations: TAFI, thrombin activatable fibrinolysis inhibitor; APC, activated protein C. | ||
| Age | Antithrombin deficiency | Hyperhomocysteinemia |
| Previous thrombosis | Protein C deficiency | High levels of factor VIII |
| Immobilization | Protein S deficiency | APC-resistance in the |
| Major surgery | Factor V Leiden | absence of factor V Leiden |
| Orthopedic surgery | Prothrombin 20210A | High levels of factor IX |
| Malignancy | Dysfibrinogenemia | High levels of factor XI |
| Oral contraceptives | High levels of TAFI | |
| Hormonal replacement therapy | ||
| Antiphospholipid syndrome | ||
| Essential thrombocythemia | ||
| Polycythemia vera | ||
| Paroxysmal nocturnal hemoglobinuria | ||